| |
Article Title |
Author(s) |
Type (Status) |
Available Online |
|
The Role of IMiDs Alone or in Combination in Prostate Cancer
DOI: 10.1016/j.clgc.2012.03.005
Abstract: Recent insights into mechanisms by which prostate cancer becomes castration resistant have allowed better and more rational therapeutic design. These novel therapies have complemented the mo...
|
Chadi Nabhan,
Daniel P. Petrylak
|
Review article
(In Press Corrected Proof)
|
21 May 2012 |
|
Neutrophil Number after Interferon-Alfa Treatment is an Independent Predictive Marker of Overall Survival in Metastatic Renal Cell Carcinoma
DOI: 10.1016/j.clgc.2012.03.006
Micro-Abstract: Immunotherapy using interferon-alpha (INF-α) is indicated for patients with metastatic renal cancer. In this study, we retrospectively evaluated the previously reported predictive mark...
|
Takeshi Azuma,
Yukihide Matayoshi,
Yasushi Nagase,
Masaya Oshi
|
Full-length article
(In Press Corrected Proof)
|
21 May 2012 |
|
Prolonged Therapy With Cabazitaxel in an Octogenarian With Metastatic Castration-Resistant Prostate Cancer
DOI: 10.1016/j.clgc.2012.03.007
|
Sumanta K. Pal,
Cy A. Stein
|
Short communication
(In Press Corrected Proof)
|
11 May 2012 |
|
A Phase II Trial of Intrapatient Dose-Escalated Sorafenib in Patients With Metastatic Renal Cell Carcinoma
DOI: 10.1016/j.clgc.2012.03.001
Micro-Abstract: Sorafenib has been demonstrated in second-line setting with limited significant adverse events at a dose of 400 mg twice a day (b.i.d.) in patients with metastatic renal cell carcinoma...
|
Robert Amato,
Jim Zhai,
James Willis,
Somyata Saxena,
Melissa DeFoe
et al.
|
Full-length article
(In Press Corrected Proof)
|
03 May 2012 |
|
Metastatic Extraosseous Ewing's Sarcoma (EES)/Primitive Neuroectodermal Tumor (PNET) of the Kidney: 8-Year Durable Response After Induction and Maintenance Chemotherapy
DOI: 10.1016/j.clgc.2012.03.004
|
Stephen L. Richey,
Priya Rao,
Christopher G. Wood,
Shreyaskumar Patel,
Nizar M. Tannir
et al.
|
Short communication
(In Press Corrected Proof)
|
16 April 2012 |
|
A Randomized Trial Comparing Tamoxifen Therapy vs. Tamoxifen Prophylaxis in Bicalutamide-Induced Gynecomastia
DOI: 10.1016/j.clgc.2012.03.002
Micro-Abstract: The activity of tamoxifen (TAM) in counteracting bicalutamide-induced breast events has been tested in 117 patients with carcinoma of the prostate. Bicalutamide-induced breast events (...
|
Vincenzo Serretta,
Vincenzo Altieri,
Giuseppe Morgia,
Federico Nicolosi,
Gaetano De Grande,
Rosaria Mazza,
Darwin Melloni,
Rosalinda Allegro,
Francesco Ferraù,
Vittorio Gebbia
et al.
|
Full-length article
(In Press Corrected Proof)
|
13 April 2012 |
|
Malignant Fibrous Histiocytoma of the Spermatic Cord in a Patient With Polycystic Kidney Disease; Review of the Literature
DOI: 10.1016/j.clgc.2012.03.003
|
Lutfiye Demir,
Alper Can,
Ahmet Dirican,
Vedat Bayoğlu,
Turkan Atasever Rezanko,
Murat Akyol,
Yuksel Kucukzeybek,
Cigdem Erten,
Mustafa Oktay Tarhan
et al.
|
Short communication
(In Press Corrected Proof)
|
09 April 2012 |
|
Cabazitaxel Rechallenge at Prostate-Specific Antigen Relapse After Previous Cabazitaxel and Docetaxel Chemotherapy: Case Report
DOI: 10.1016/j.clgc.2012.01.011
|
Christina J. Perry,
Santhanam Sundar
|
Short communication
(In Press Corrected Proof)
|
26 March 2012 |
|
Enduring Response to Everolimus as Third-Line Therapy in a Patient With Advanced Renal Cell Carcinoma, Including Small-Bowel Metastases: Loss of FHIT but Normal VHL Gene Status
DOI: 10.1016/j.clgc.2012.01.008
|
Reuben J. Broom,
Imogen Caldwell,
Fritha Hanning,
Peter Fong,
Sanjeev Deva,
Paul Oei
et al.
|
Short communication
(In Press Corrected Proof)
|
22 March 2012 |
|
Prostate Cancer Stem Cells
DOI: 10.1016/j.clgc.2012.01.002
Abstract: Stem cells have long been implicated in prostate gland formation. The prostate undergoes regression after androgen deprivation and regeneration after testosterone replacement. Regenerative s...
|
Shi-Ming Tu,
Sue-Hwa Lin
|
Review article
(In Press Corrected Proof)
|
16 March 2012 |
|
Spontaneous Regression of Thoracic Metastases While Progression of Brain Metastases After Stereotactic Radiosurgery and Stereotactic Body Radiotherapy for Metastatic Renal Cell Carcinoma: Abscopal Effect Prevented by the Blood-Brain Barrier?
DOI: 10.1016/j.clgc.2012.01.004
|
Hiromichi Ishiyama,
Bin S. Teh,
Hua Ren,
Stephen Chiang,
Anne Tann,
Angel I. Blanco,
Arnold C. Paulino,
Robert Amato
et al.
|
Short communication
(In Press Corrected Proof)
|
14 March 2012 |
|
A Primary Signet Ring Cell Carcinoma of the Prostate With Bone Metastasis With Impressive Response to FOLFOX and Cetuximab
DOI: 10.1016/j.clgc.2012.01.006
|
Ana Milena Roldán,
Natalia Fernández Núñez,
Enrique Grande,
Augusto Álvarez García,
Luis M. Antón-Aparicio
et al.
|
Short communication
(In Press Corrected Proof)
|
14 March 2012 |
|
Development of Novel Immune Interventions for Prostate Cancer
DOI: 10.1016/j.clgc.2012.01.012
Abstract: Prostate cancer is the leading cause of cancer-related morbidity and mortality in men in the Western world. Use of traditional and newer therapeutic regimens is constrained in terms of toler...
|
Neeraj Agarwal,
Sumanth Padmanabh,
Nicholas J. Vogelzang
|
Review article
(In Press Corrected Proof)
|
14 March 2012 |
|
Response of Metastatic Renal Medullary Carcinoma to Carboplatinum and Paclitaxel Chemotherapy
DOI: 10.1016/j.clgc.2012.01.003
|
Venu gopala reddy Gangireddy,
Georgia B. Liles,
Gilberto D. Sostre,
Teresa Coleman
|
Short communication
(In Press Corrected Proof)
|
14 March 2012 |
|
Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer: A Systematic Diagnostic Attempt
DOI: 10.1016/j.clgc.2011.12.004
Micro-Abstract: We propose a composite and reproducible neuroendocrine differentiation (NED)– assessing panel—including plasma chromogranin A (p-CgA), tissular CgA (t-CgA), somatostatin receptor 2 (SS...
|
Deliu-Victor Matei,
Giuseppe Renne,
Marcelo Pimentel,
Maria Teresa Sandri,
Laura Zorzino,
Edoardo Botteri,
Concetta De Cicco,
Gennaro Musi,
Antonio Brescia,
Federica Mazzoleni,
Valeria Tringali,
Serena Detti,
Ottavio de Cobelli
et al.
|
Full-length article
(In Press Corrected Proof)
|
09 March 2012 |
|
Prevalence and Predictors of Benign Lesions in Renal Masses Smaller Than 7 cm Presumed to be Renal Cell Carcinoma
DOI: 10.1016/j.clgc.2012.01.005
Micro-Abstract: The present study was designed to determine the incidence and predictive factors of benign renal lesions in 450 patients who underwent surgical removal of solitary renal masses <7 c...
|
Bulent Akdogan,
Ahmet Gudeloglu,
Kubilay Inci,
Levent Mert Gunay,
Artan Koni,
Haluk Ozen
et al.
|
Full-length article
(In Press Corrected Proof)
|
09 March 2012 |
|
Phase II Trial of Weekly Ixabepilone in Men With Metastatic Castrate-Resistant Prostate Cancer (E3803): A Trial of the Eastern Cooperative Oncology Group
DOI: 10.1016/j.clgc.2012.01.009
Micro-Abstract: Ixabepilone is an epothilone B analogue with activity in a variety of solid malignancies, including prostate cancer. The main dose-limiting toxicity of ixabepilone is myelosuppression ...
|
Glenn Liu,
Yu-Hui Chen,
Robert DiPaola,
Michael Carducci,
George Wilding
et al.
|
Full-length article
(In Press Corrected Proof)
|
05 March 2012 |
|
Expression of microRNAs in the Urine of Patients With Bladder Cancer
DOI: 10.1016/j.clgc.2012.01.001
Micro-Abstract: We quantified the urine sediment and supernatant levels of microRNA (miRNA) targets related to epithelial-mesenchymal transition in 51 patients with bladder cancer and in 24 controls. ...
|
Gang Wang,
Eddie Shu-Yin Chan,
Bonnie Ching-Ha Kwan,
Philip Kam-Tao Li,
Sidney Kam-Hung Yip,
Cheuk-Chun Szeto,
Chi-Fai Ng
et al.
|
Full-length article
(In Press Corrected Proof)
|
05 March 2012 |
|
Ras Association Domain Family 1A: A Promising Prognostic Marker in Recurrent Nonmuscle Invasive Bladder Cancer
DOI: 10.1016/j.clgc.2011.12.003
Micro-Abstract: The aim of this study was to investigate the value of RASSF1A methylation as a prognostic marker in bladder cancer. RASSF1A hypermethylation from 301 specimens of primary BC tissue was...
|
Ji Sang Kim,
Yunbyung Chae,
Yun-Sok Ha,
Isaac Yi Kim,
Seok Soo Byun,
Seok-Joong Yun,
Wun-Jae Kim
et al.
|
Full-length article
(In Press Corrected Proof)
|
01 March 2012 |
|
Importance of Fibroblast Growth Factor Receptor in Neovascularization and Tumor Escape from Antiangiogenic Therapy
DOI: 10.1016/j.clgc.2012.01.010
Abstract: Therapeutic inhibition of pathways involved in angiogenesis has become the standard of care in renal cell carcinoma (RCC). Most currently available antiangiogenic agents inhibit the vascular...
|
Philip J. Saylor,
Bernard Escudier,
M. Dror Michaelson
|
Review article
(In Press Corrected Proof)
|
01 March 2012 |
|
Epidemiologic Trends in Renal Cell Carcinoma in the Cytokine and Post-Cytokine Eras: A Registry Analysis of 28,252 Patients
DOI: 10.1016/j.clgc.2012.01.007
Micro-Abstract: Advances in the targeted treatment of renal cell cancer (RCC) have shown improvements in survival in clinical trials and have largely replaced cytokine therapies as the standard of car...
|
Derek Shek,
Benjamin Tomlinson,
Monica Brown,
Ann Brunson,
Chong-Xian Pan,
Primo N. Lara
et al.
|
Full-length article
(In Press Corrected Proof)
|
01 March 2012 |
|
A Case Report of Putative Autoimmunity to Prostate Cancer After Immune-Mediated Rejection of Melanoma Through a Shared Tumor Antigen
DOI: 10.1016/j.clgc.2011.12.002
|
Polly Gregor,
Q. Daisy Huang,
Humilidad F. Gallardo,
Teresa S. Rasalan,
Michael J. Morris
et al.
|
Short communication
(In Press Corrected Proof)
|
27 January 2012 |
|
Complete Response After Sequential Sunitinib-Sorafenib Treatment In a Patient With Renal Cell Carcinoma: A Case Report
DOI: 10.1016/j.clgc.2011.11.006
|
Elena Verzoni,
Rodolfo Lanocita,
Giuseppe Procopio
|
Short communication
(In Press Corrected Proof)
|
09 January 2012 |